usharma@gitam.edu
LinkedIn
Google Scholar
Scopus
ORCiD
Dr. Umakant Sharma completed his Ph.D. from AIIMS, New Delhi. He was an ICMR-Fellow. He had postdoctoral from University of Minnesota, USA. He was a Research Assistant Professor at University of Miami, USA. His primary research focuses on metagenomics, metabolomics, cancer, EcoHIV, inflammatory, and infectious diseases and precisely on the development of novel personalized therapy using signature gut microbiome and metabolites for the treatment of Inflammatory bowel diseases and colon cancer.
Research Publications
- 1. Sharma U, Olson RK, Erhart FN, Zhang L, Meng J, Segura B, Sharma M, Banerjee S, Saluja AK, Ramakrishnan S, Abreu MT and Roy S. Prescription opioids induce gut dysbiosis and exacerbate Inflammatory Bowel Disease. J Crohns Colitis 2020: 14(6); 801-817. DOI: 10.1093/ecco-jcc/jjz188
- 2. *Sindberg GM, *Sharma U, Banerjee S, Anand V, Dutta R, Gu CJ, Volsky DJ & Roy S. An Infectious Murine Model for Studying the Systemic Effects of Opioids on Early HIV Pathogenesis in the Gut. J Neuroimmune Pharmacol 2015: 10(1); 74-87. DOI: 10.1007/s11481-014-9574-9 *(authors contributed equally)
- 3. Banerjee S, Sindberg G, Wang F, Meng J, Sharma U, Zhang L, Dauer P, Chen C, Dalluge J, Johnson T and Roy S. Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunol 2016: 9(6); 1418-1428. DOI: https://doi.org/10.1038/mi.2016.9.
- 4. Sethi V, Kurtom S, Tarique M, Lavania S, Malchiodi Z, Hellmund L, Zhang L, Sharma U, Giri B, Garg B, Ferrantella A, Vickers SM, Banerjee S, Dawra R, Roy S, Ramakrishnan S, Saluja A and Dudeja V. Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response. Gastroenterology 2018: 155(1); 33-37. DOI: 10.1053/j.gastro.2018.04.001.
- 5. Ghosh N, Kesh K, Singh PK, Sharma U, Chupikova I, Ramakrishnan S, and Roy S. Morphine use induces gastric microbial dysbiosis driving gastric inflammation through TLR2 signaling which is attenuated by proton pump inhibitor. Br J Pharmacol 2022: DOI: 10.1111/bph.16025.
Ongoing Research Projects
-
1. Evaluation of therapeutic potential of synbiotics (probiotics+ prebiotics) and metabolite Consortia on Amelioration of Inflammation and Clinical Manifestations of Inflammatory bowel diseases (IBD) and Colon cancer.
-
2. Development of effective personalized therapies using gut microbiome and metabolites for the treatment of Inflammatory bowel diseases (IBD) and colon associated cancer (CAC).
-
3. Development of novel diagnostic tools using signature gut microbiome and metabolites for the diagnosis of Inflammatory bowel diseases (IBD) and colorectal cancer (CRC).
-
4. Drug Induced Dysregulation of Gut Microbiota and Systemic Inflammation Accelerate HIV-Associated Premature Aging in a murine Model of HIV.
-
5. Investigation of anti-inflammatory activity of natural compounds in In-vitro and In-vivo models.
Expertise
-
1. Establishing research collaboration
-
2. Research grant writing to receive the funding
-
3. Editorial board member and Reviewer of the Peer-reviewed Journals
-
4. Mentoring Ph.D students and Research Scholars
-
5. Research experimentation in mouse model.
Authored Books
-
N/A
